Prostate Cancer

Increased prostate cancer screening has led to overtreatment and has not significantly reduced mortality rates in prostate cancer.

PROSTVAC-VF uses the smallpox viral vector to stimulate the immune system.

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

New data show that most prostate cancer patients who receive androgen-deprivation therapy gain a significant amount of weight within a year of starting treatment

Many clinicians are not employing radiation therapy used in combination with androgen deprivation therapy even though guidelines suggest they should

New data suggested that hospitals that purchase a surgical robot experience a subsequent hike in the number of radical prostatectomies

Men with advanced CRPC who were treated with abiraterone acetate plus prednisone/prednisolone had significant improvement in overall survival

Donna Berry Discusses Her Prostate Cancer Research

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process

Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

Dr. Markman Discusses the Swedish PSA Screening

Dr. Pecora on Results from the Swedish PSA Study

Dr. Markman Discusses the Importance of Cancer Screening

Dr. Pecora Evaluates the Prostate, Lung, Colorectal and Ovarian Cancer Study Findings

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

Abiraterone acetate gains FDA approval by demonstrating the ability to extend survival in patients with metastatic castrate-resistant prostate cancer

Dr. Crawford Discusses Alternatives to Biopsy in Prostate Cancer

The difficulties with choosing a prostate cancer treatment were highlighted once again by a recent study published in the Journal of Urology

Translational medicine is currently the focus of much attention in the medical and research community and is the wave of the foreseeable future

E. David Crawford, MD from the University of Colorado Health Sciences Center Talks About 3D Mapping Biopsies

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies